AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation - AstraZeneca ( NASDAQ:AZN )

Yesterday

The FDA approved on Wednesday AstraZeneca Plc's AZN Fasenra ( benralizumab ) for eosinophilic granulomatosis with polyangiitis ( EGPA ) , a rare, immune-mediated vasculitis ( inflammation of the blood vessels ) that can result in damage to multiple organs.

Ticker	Sentiment	Impact
AZN	Somewhat Bearish	48 %